Tesamorelin and neurocognitive impairment in people with HIV and abdominal obesity
Within-group cognitive score improved numerically with tesamorelin, but the between-group difference was not significant (P=0.673); waist circumference declined more with tesamorelin.
What this study tells us
This was an early human study designed mainly to measure exposure, tolerability or a preliminary signal. Without stronger blinded controls, it should not be treated as definitive proof of benefit.
Virally suppressed people with HIV, abdominal obesity and neurocognitive impairment
n=73
Within-group cognitive score improved numerically with tesamorelin, but the between-group difference was not significant (P=0.673); waist circumference declined more with tesamorelin.
Underpowered, no placebo arm, short duration; does not demonstrate cognitive efficacy.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Within-group cognitive score improved numerically with tesamorelin, but the between-group difference was not significant (P=0.673); waist circumference declined more with tesamorelin.